Bristol Myers Squibb partnered with AI company Chai Discovery. The collaboration aims to develop new antibody-based therapies.
Bristol Myers will utilize Chai Discovery's artificial intelligence platform. This platform includes molecular folding and design models. The goal is to accelerate identifying therapeutic antibody candidates.
The partnership aims to shorten drug discovery timelines. It will also explore therapeutic targets difficult to address with traditional methods.
Financial terms of the deal were not disclosed. Bristol Myers Squibb joins major pharmaceutical companies partnered with Chai Discovery. These companies include Eli Lilly, Pfizer, and Novartis. Chai Discovery is a San Francisco-based AI firm.